Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers
November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.
MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer
November 9th 2020Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.
ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC
November 9th 2020Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.
Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer
The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.
TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain
Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.
Management of Small Cell Lung Cancer Moves Forward With Immunotherapy
November 7th 2020Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.
Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing
November 7th 2020Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC
Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.
Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC
November 10th 2019Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.
Neoadjuvant Approaches Showcase Advantages in NSCLC
Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.
Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options
November 13th 2018In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.
Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC
November 13th 2018Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.
Broad Panel NGS Testing Grows in Value for NSCLC
November 11th 2018Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.